Piper Sandler Raised the Firm’s PT on ABIVAX Société (ABVX), Kept an Overweight Rating

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Best All-Time High Stocks to Buy According to AnalystsOn July 29, Piper Sandler raised the firm’s price target on ABIVAX Société Anonyme (NASDAQ:ABVX) from $70 to $112, while keeping an Overweight rating on the stock.

The upgraded price target comes after the firm analysed Phase 3 induction data for ABIVAX Société Anonyme’s (NASDAQ:ABVX) drug Obefazimod in ulcerative colitis. The firm also noted that it is fair to add the revenue potential from early-line UC treatments, which doubles its US UC revenue forecast to €2,656 million by 2035.

Piper Sandler Raised the Firm’s PT on ABIVAX Société (ABVX), Kept an Overweight Rating

A biotechnologist in a lab setting, examining a sample of liquid for research and development.

The analyst believes there is significant upside for the ABIVAX Société Anonyme (NASDAQ:ABVX) ahead of key upcoming data releases. This includes full induction data presentations and maintenance data expected in 2026.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops treatments for chronic inflammatory diseases like ulcerative colitis and Crohn’s disease.

While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.